

2025: A Bright Year Ahead for Future Pharmacology

 Fabrizio Schifano [†] 

Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK; f.schifano@herts.ac.uk

[†] Editor-in-Chief of Future Pharmacology.

As 2024 is coming to an end, let us reflect on *Future Pharmacology*'s achievements to better understand what is promising to be a bright year ahead. The *Future Pharmacology* team remains steadfast in its mission to promote open science, enabling scientists to collaborate more effectively and rapidly in order to provide innovative clinical solutions for complex medical issues. This will be carried out with current and future research being published, with all these academic outputs being both validated and of high quality.

An overview of the 2024 data for *Future Pharmacology* may help to better assess our overall improvement in quality and scientific outputs. So far, we have published 49 papers. Dr. Giuseppe Floresta from the University of Catania, Italy, has recently been added as a new editorial board member. An Early Career Editorial Board (ECEB) Project has been announced (<https://www.mdpi.com/journal/futurepharmacol/announcements/9245>), and the first Early Career Editorial Board of *Future Pharmacology* will be established soon.

We had the opportunity to promote *Future Pharmacology* at various events in 2024 (Table 1).

Table 1. Range of sponsored conferences.

Conference Name	Location
2024 CSPS/CC-CRS Symposium	Edmonton, Canada
CRS 2024 Annual Meeting and Exposition	Bologna, Italy
15th APS PharmSci International Conference	Huddersfield, UK
The 17th Chinese Pharmaceutical Conference 2024	Hangzhou, China
Pharmacology 2024	Harrogate, UK



Received: 23 December 2024

Accepted: 23 December 2024

Published: 1 January 2025

Citation: Schifano, F. 2025: A Bright Year Ahead for Future Pharmacology.

Future Pharmacol. **2025**, *5*, 2.

<https://doi.org/10.3390/futurepharmacol5010002>
Copyright: © 2025 by the author. Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons

Attribution (CC BY) license

 (<https://creativecommons.org/licenses/by/4.0/>).

I am pleased to inform you that, over the last 12 months, the three papers have attracted the most views (Table 2).

Table 2. Most viewed papers over the last 12 months.

Title	Views
Therapeutic Use of Palmitoylethanolamide as an Anti-Inflammatory and Immunomodulator	5643
Hereditary Angioedema: Novel Molecules for Treatment of Acute Attacks and Long-Term Prophylaxis	3904
Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future	3846

Finally, I will share some excellent news related to Indexing! Our journal was indexed in the Emerging Sources Citation Index (ESCI)—Web of Science (Clarivate Analytics) in

May 2024 (<https://www.mdpi.com/journal/futurepharmacol/history>) and will receive its first Impact Factor in 2025!

Maintaining quality and integrity is integral to our dedication to the research community and is reflected in all our activities. This year, we have focused on rejecting problematic submissions and ensuring precision in our desk review rejections. Additionally, we prioritize providing an excellent publishing experience for researchers in our community.

From everyone here at *Future Pharmacology* and myself, we wish you all the best for the holiday season and the new year.

Funding: This research received no external funding.

Conflicts of Interest: The author declares no conflicts of interest.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.